Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2015 / Jan / This month in business
Professional Development Business and Entrepreneurship

This month in business

Remember Allergan’s eyeing-up of Salix?

1/12/2015 1 min read

Share

0115-205-mainPhoto Credit: Herval, Flickr

Back when Allergan was trying to avoid takeover by Valeant, they looked at buying the specialist pharmaceutical company, Salix, for US$11 billion. Why? Doing so would wipe out their particularly attractive net cash proportion. It appears that Salix was suffering from inventory issues – wholesalers had amassed too much stock of their biggest-selling products, Uceris, Apriso and Xifaxan. Salix’s Q4 2014 and Q1 2015 sales will therefore have suffered. After their deal with Allergan fell through, Salix was then briefly courted by Actavis – who went on to buy Allergan instead.

EMA’s CHMP recommend Chiesi’s Holoclar for limbal stem cell deficiency Chiesi Farmaceutici S.p.A.’s Holoclar – an ex vivo autologous corneal epithelial cell preparation (that includes stem cells) has been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval in the EU. The recommended indication is for the treatment of adult patients with moderate to severe limbal stem cell deficiency, and Holoclar is the first advanced therapy medicinal product containing stem cells receive this recommendation.

Alcon’s Travatan label is expanded Travatan (travoprost 40 μg/mL eyedrops) has a new indication in the EU: the “decrease of elevated intraocular pressure in pediatric patients aged 2 months to <18 years with ocular hypertension or pediatric glaucoma.” The European Medicines Agency gave approval based principally on the results of a multicenter, double-blind Phase III clinical trial (NCT01652664), which showed that travoprost therapy was associated with a reduced IOP by the second week of treatment, which was maintained throughout the 12  weeks of the study.

FDA gives the thumbs-up to RESCAN 700, ranibizumab in diabetic retinopathy, and MANF for RP. The FDA has given marketing approval for Zeiss’ intraoperative OCT, RESCAN 700, as well as granting breakthrough therapy designation for ranibizumab for the treatment of diabetic retinopathy. Amarantus BioScience’s mesencephalic astrocyte-derived neurotrophic factor (MANF) – an apoptosis inhibitor/ growth factor – has also received orphan drug designation for retinitis pigmentosa. Preclinical studies have shown protective effects in the retina, and toxicology studies have demonstrated MANF to be well-tolerated after a single intravitreal administration of a therapeutically relevant dose.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: